Online versions of scientific journals Current user: guest        
Hide Left Menu
Temporary Collection

Customer support
» support service
» FAQ
» help
Abstract of article
Bioorganicheskaya khimiya

 -  tom 33, № 1, Yanvar'-Fevral' 2007, S. 148-155 Help

[ Previous / Next Abstract | Issue Contents | Bottom of Page ] Delete from Cart Add to Cart Delete from Collection Add to Collection

Product Price:  20.00 USD;  Product Discount:  0.0%;

Full Text: [PDF (268Kb)] |  
 
NOVYE KON"YuGATY PROTIVOOPUKhOLEVOGO ANTIBIOTIKA DOKSORUBITsINA S VODORASTVORIMYM GALAKTOMANNANOM: SINTEZ I BIOLOGIChESKAYa AKTIVNOST'
A. N. Tevyashova1, E. N. Olsuf'eva1, M. N. Preobrazhenskaya1, A. A. Klesov2, E. Zomer2, D. Platt2
1NII po izyskaniyu novykh antibiotikov im. G.F. Gauze RAMN, 119021, Moskva, B. Pirogovskaya ul., 11;
2Pro-Farmas'yutikals, 189 Vells Avenyu, N'yuton 02459 MA, SShA

Postupila v redaktsiyu 07.04.2006 g.
V okonchatel'noi redaktsii 24.05.2006 g.
Klyuchevye slova: doksorubitsin, kon"yugaty, antiproliferativnaya aktivnost', 1,4-β-D-galaktomannan.

Vzaimodeistviem okislennogo periodatom vodorastvorimogo galaktomannana s doksorubitsinom ili N-(L-lizil)doksorubitsinom polucheny sootvetstvuyushchie novye vodorastvorimye kon"yugaty v vide osnovanii Shiffa (DGM-1 i DGM-2). Vodorastvorimyi galaktomannan (DAVANATŽ, kommercheskii produkt firmy “Pro-Pharmaceuticals”) poluchen iz vysokomolekulyarnogo galaktomannana semyan rasteniya Cyamopsis tetragonoloba (guarovaya kamed') putem chastichnogo kislotnogo gidroliza. Izuchena ustoichivost' kon"yugatov v vodnykh rastvorakh. Antiproliferativnaya aktivnost' DGM-1 na modelyakh – kletochnykh liniyakh myshinoi melanomy B16-F1, raka grudi cheloveka MCF-7 (HTB-22) i raka tolstoi kishki cheloveka HT-29 (HTB-38) sopostavima s takovoi dlya doksorubitsina. DGM-2 maloaktiven vo vsekh trekh testakh. Na osnovanii poluchennykh dannykh DGM-1 mozhno rassmatrivat' kak vysokomolekulyarnuyu depo-formu doksorubitsina.

Spisok literatury

  1. Garin A.M., Khlebnov A.V. Spravochnik prakticheskoi khimioterapii opukholei. M.: Asta Medika AG, 1995.
  2. Arcamone F. Doxorubicin anticancer antibiotics. London, New-York;
    San Francisco: Acad. Press, 1981.
  3. Pratesi G., Monestiroli S.V. // Curr. Med. Chem. 2001. V. 8. P. 9–13.
  4. Perevodchikova N.I., Preobrazhenskaya M.N. // Novye tsitostatiki v lechenii zlokachestvennykh opukholei / Red. Gorbunova V.A. M., 1998. C. 61–74.
  5. Monneret C. // Eur. J. of Med. Chem. 2001. V. 36. P. 483–493.
  6. Olsuf'eva E.N. // Bioorgan. khimiya. 1990. T. 16. C. 1445–1463.
  7. Olsuf'eva E.N. // Bioorgan. khimiya. 1992. T. 18. C. 149–180.
  8. Damen E., De Groot F., Scheeren H. // Expert Opinion on Therapeutic Patents. 2001. V. 11. P. 651–666.
  9. De Groot F., Damen E., Scheeren H. // Curr. Med. Chem. 2001. V. 8. P. 1093–1122.
  10. Seymour L. // Crit. Rev. Ther. Drug Carrier Syst. 1992. V. 9. P. 135–187.
  11. Rihova B., Etrych T., Pechar M., Jelinkova M., Stastny M., Hovorka O., Kovar M., Ulbrich K. // J. Control Release. 2001. V. 74. P. 225–232.
  12. Kopeckova D., Minko T., Rubinstein A., Kopecek J. // Eur. J. Cancer. 2004. V. 40. P. 148–157.
  13. Jelinkova M., Storhaln J., Etrych T., Ulrich K., Rihova B. // Pharm. Res. 2003. V. 20. P. 1558–1564.
  14. Langer M., Kratz F., Rothen-Rutishauser B., Wunderli-Allenspach H., Beck-Sickinger A. // J. Med. Chem. 2001. V. 44. P. 1341–1348.
  15. Lutsenko S., Feldman N., Severin S. // J. Drug Target. 2002. V. 10. P. 567–571.
  16. Kratz F., Beyer U., Collery P., Lechenault F., Cazabat A., Schumacher P., Falken U., Unger C. // Biol. Pharm. Bull. 1998. V. 21. P. 56–61.
  17. Domb A.J., Benita S., Polacheck I., Linden G. Patent US 6011008. 2000. CA 2000. V. 132. P. 69331.
  18. Vogel C.-W. Immunoconjugates. Antibody conjugates in radioimaging and therapy of cancer. Oxford: Oxford University Press, 1987. P. 189–217.
  19. Aboud-Pirak E., Hurwitz E., Bellot F., Schlessinger J., Sela M. // Proc. Natl. Acad. Sci. USA. 1989. V. 86. P. 3778–3781.
  20. Hurwitz E., Maron R., Arnon R., Wilcher M., Sela M. // Eur. J. Cancer. 1978. V. 14. P. 1213–1220.
  21. Ahmad S., Tester R. //22nd Intern. Carbohydrate Symp. Abstr. 23–27 July 2004. Glasgow, UK, C37.
  22. Olsufyeva E.N., Tevyashova A.N., Trestchalin I.D., Preobrazhenskaya M.N., Platt D., Klyosov A. // Carbohydrate Res. 2003. V. 338. P. 1359–1367.
  23. El Khadem H.S. Anthracycline antibiotics. New York: Acad. Press, 1982. P. 124–138.
  24. Silverman R. Organic chemistry of drug design and drug action: San Diego: Elsevier Acad. Press, 2004.
  25. Vasta G.R., Ahmed H., Odom E.W. // Curr. Opinion in Struct. Biology. 2004. V. 14. P. 616–630.
  26. Debray C., Vereecken P., Belot N., Tiellard P., Brion J.-P., Pandolfo M., Pochet R. // Biochem. and Biophys. Res. Communs. 2004. V. 325. P. 1393–1398.
  27. Cairo C.W., Gestwicki J.E., Kanai M., Kiessling L.L. // JACS. 2002. V. 124. P. 1615–1619.
  28. Klyosov A.A., Platt D., Zomer E. // Preclinica. 2003. V. 1. P. 175–186.
  29. Levin Y., Sela B. // Curr. Chemotherapy and Infections. 1980. V. 25. P. 1685–1687.
  30. AnaSpec, Inc., San Jose, CA 95131, cast number 22501.


PII: S0132342307010150

[ Previous / Next Abstract | Issue Contents | Top of Page ]